Agios Pharmaceuticals Inc., a Cambridge biopharmaceutical focused on the field of cancer metabolism, has named John Maraganore, CEO of Alnylam Pharmaceuticals, to its board of directors.
Maraganore is Agios’ first independent director on the five-member board.
Agios is working to discover and develop novel therapeutics in cancer metabolism, building a platform integrating cancer biology, metabolomics, biochemistry and informatics to enable target and biomarker identification, with a goal of being able to manipulate cancer cells’ metabolism.
Maraganore joined Alnylam in 2002. Before that he was on the management team for Millennium Pharmaceuticals Inc., where he was responsible for the company’s product franchises in oncology, cardiovascular, inflammation, and metabolic diseases.
In April, Agios made a pair of announcements, reporting an $8.8 million venture round , and signing a $130 million agreement to collaborate with New Jersey-based Celgene Corp. in the development of potential cancer-fighting therapies.
